Subgroup analyses showed the benefit of fibrates on the primary composite outcome to be consistent irrespective of age , gender , and diabetes mellitus .
Moderate evidence showed that the fibrate class can be effective in the secondary prevention of composite outcome of non-fatal stroke , non-fatal MI , and vascular death .
However , this beneficial effect relies on the inclusion of clofibrate data , a drug that was discontinued in 2002 due to its unacceptably large adverse effects .
BACKGROUND Fibrates are a class of drugs characterised by mainly lowering high triglyceride , raising high-density lipoprotein ( HDL ) cholesterol , and lowering the small dense fraction of low-density lipoprotein ( LDL ) cholesterol .
Their efficacy for secondary prevention of serious vascular events is unclear , and to date no systematic review focusing on secondary prevention has been undertaken .
OBJECTIVES To assess the efficacy and safety of fibrates for the prevention of serious vascular events in people with previous cardiovascular disease ( CVD ) , including coronary heart disease and stroke .
Treatment of Hypercholesterolemia and Combined Hyperlipidemia With Simvastatin and Gemfibrozil in Patients With NIPPM: A multicenter comparison study
OBJECTIVE To compare the lipid-lowering efficacies of simvastatin and gemfibrozil in NIDDM patients with combined ( mixed ) hyperlipidemia ( CHL ) or isolated hypercholesterolemia ( IHC ) . RESEARCH DESIGN AND METHODS Patients with primary dyslipidemia and NIDDM were recruited for this double-blind , double-dummy comparison study from 10 Finnish centers . After a 4-week placebo run-in period , they were r and omly assigned to simvastatin or gemfibrozil . The simvastatin group ( n = 47 ) received 10 mg once nightly for 8 weeks , 20 mg for the next 8 weeks , and 40 mg for the third 8-week period . The gemfibrozil group ( n = 49 ) received 600 mg twice daily throughout the 24 weeks . The lipid-lowering efficacies of both drugs were compared in all patients as well as separately in patients with CHL and IHC . RESULTS In all patients , simvastatin reduced LDL and total cholesterol and the LDL-to-HDL cholesterol ratio more effectively , whereas gemfibrozil was more effective in elevating HDL cholesterol and decreasing triglyceride levels . The drug effects differed according to lipid phenotype at baseline . Simvastatin decreased LDL cholesterol levels by 30–40 % in both phenotypes . Gemfibrozil caused a 15 % reduction in LDL cholesterol in IHC but no change in CHL patients . Simvastatin produced 15–30 % reductions in triglyceride levels in CHL but no change in IHC patients . Gemfibrozil caused reductions in triglycerides in CHL ( 50 % and more ) and in IHC ( 40 % ) patients , with 12–18 % increases in HDL cholesterol in these groups . CONCLUSIONS Simvastatin is useful in both CHL and IHC patients , whereas gemfibrozil can be used in patients with high triglyceride and low or normal LDL cholesterol levels
Subgroup analyses showed the benefit of fibrates on the primary composite outcome to be consistent irrespective of age , gender , and diabetes mellitus .
Moderate evidence showed that the fibrate class can be effective in the secondary prevention of composite outcome of non-fatal stroke , non-fatal MI , and vascular death .
However , this beneficial effect relies on the inclusion of clofibrate data , a drug that was discontinued in 2002 due to its unacceptably large adverse effects .
BACKGROUND Fibrates are a class of drugs characterised by mainly lowering high triglyceride , raising high-density lipoprotein ( HDL ) cholesterol , and lowering the small dense fraction of low-density lipoprotein ( LDL ) cholesterol .
Their efficacy for secondary prevention of serious vascular events is unclear , and to date no systematic review focusing on secondary prevention has been undertaken .
OBJECTIVES To assess the efficacy and safety of fibrates for the prevention of serious vascular events in people with previous cardiovascular disease ( CVD ) , including coronary heart disease and stroke .